NextPharma sells off U.S. CMO operation

CMO NextPharma has sold its U.S. manufacturing operation, Bioserv, to private equity player KESA Partners for an undisclosed sum, planning to focus on its core European operation.

The U.K. company bought Bioserv in 2007, and the divestment will help it bear down on its manufacturing specialties, which include hormones, penicillins, and cephalosporins, CEO Franck Latrille said.

With the acquisition, KESA gets Bioserv's 35,000-square-foot San Diego facility and capabilities in aseptic and non-aseptic bulk formulation, filtration, stoppering and lyophilization services. Furthermore, the CMO has a reputation among clients for its quality, flexible service, KESA Managing Partner Al Hansen said.

"Bioserv has a strong foundation to build upon and to add capabilities to its current service offering," Hansen said in a statement. "By enhancing our capabilities and emphasizing excellence in quality and execution, Bioserv will become a leader in the contract manufacturing space."

NextPharma has continued to expand its European operations, specifically in Germany, cutting the ribbon on a new cold chain facility in Werne in February, and last year unveiling new encapsulation/over-encapsulation capabilities at its clinical trial supply plant in Göttingen.

- read the announcement

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

Analytica Laser has a novel system which the company touts as the industry's first dynamic tool to predict real-world health outcomes.

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.